FindTrial
Sign In

Autologous Bone Marrow derived cells for the treatment of chronic arterial Limb Ischemia in patients with high risk of amputation

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-520937-22-00
Enrollment
21
Registered
2025-02-04
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced chronic ischemia (fontaine III-IV class and Rutherford IV-V), with risk of amputation of at least one limb

Brief summary

Anatomic and functional changes derived from the vasculo/angiogenesis induced by somatic cell therapy: improve in ankle/brachial index, digit/brachial index, transcutaneous oxygen measurement, ischemic ulcer size and maximum walking distance until claudication

Interventions

DRUGSALINE

Sponsors

Fundacion Para La Investigacion Y La Innovacion Biosanitaria Del Principado De Asturias
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Anatomic and functional changes derived from the vasculo/angiogenesis induced by somatic cell therapy: improve in ankle/brachial index, digit/brachial index, transcutaneous oxygen measurement, ischemic ulcer size and maximum walking distance until claudication—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026